ResMed (RMD) reported $1.35 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.2%. EPS of $2.55 for the same period compares to $2.08 a year ago.
The reported revenue represents a surprise of +1.87% over the Zacks Consensus Estimate of $1.32 billion. With the consensus EPS estimate being $2.46, the EPS surprise was +3.66%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- U.S., Canada, and Latin America- Devices: $432.8 million compared to the $435.08 million average estimate based on five analysts. The reported number represents a change of +6.6% year over year.
- U.S., Canada, and Latin America- Masks and other: $359.2 million compared to the $349.01 million average estimate based on five analysts. The reported number represents a change of +11.8% year over year.
- Combined Europe, Asia, and other markets- Total: $389 million versus $371.49 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +13.1% change.
- Combined Europe, Asia, and other markets- Devices: $261.1 million versus the five-analyst average estimate of $246.43 million. The reported number represents a year-over-year change of +14.1%.
- Combined Europe, Asia, and other markets- Masks and other: $127.9 million versus $125.06 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +11.2% change.
- U.S., Canada, and Latin America- Total: $791.9 million compared to the $784.09 million average estimate based on five analysts. The reported number represents a change of +8.9% year over year.
- Global revenue- Total Sleep and Breathing Health: $1.18 billion versus $1.16 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.
- Global revenue- Residential Care Software: $167 million compared to the $166.5 million average estimate based on six analysts. The reported number represents a change of +9.9% year over year.
- Global revenue- Total Devices: $693.9 million versus the five-analyst average estimate of $681.51 million. The reported number represents a year-over-year change of +9.3%.
- Global revenue- Total Masks and other: $487.1 million versus $474.07 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +11.7% change.
View all Key Company Metrics for ResMed here>>>
Shares of ResMed have returned +8.4% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ResMed Inc. (RMD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
